Topics
March 2012 | Perspectives: from The Editors Of New Retina Md
The Sunshine Act's Intimidation Factor
Will the noble objectives of this law set up a roadblock to innovation?
Richard S. Kaiser, MD, and Jonathan L. Prenner, MD
October 28, 2026
Nacuity Pharmaceuticals Doses First Patient in Phase 3 Trial of NPI-001 for the Treatment of RP Associated with Usher Syndrome
October 27, 2026
Glaukos Announces License Agreement with RevOpsis Therapeutics for Retinal Therapy
October 26, 2026
Research Identifies Previously Unrecognized Outflow Pathway
October 22, 2026
FDA Clears Opus Genetics' IND Application for OPGx-RDH12 Gene Therapy in Leber Congenital Amaurosis
October 2026 Insert
Editorially Independent Content, Supported With Advertising From Asetllas
Editorially independent supported by Abbvie and Regenxbio
Free Print Subscription
Email Newsletter
Conference Calendar
